Review ArticleReview
Current cancer burden in China: epidemiology, etiology, and prevention
Maomao Cao, He Li, Dianqin Sun, Siyi He, Xinxin Yan, Fan Yang, Shaoli Zhang, Changfa Xia, Lin Lei, Ji Peng and Wanqing Chen
Cancer Biology & Medicine August 2022, 19 (8) 1121-1138; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0231
Maomao Cao
1Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College/Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implement, Beijing 100021, China
He Li
1Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College/Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implement, Beijing 100021, China
Dianqin Sun
1Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College/Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implement, Beijing 100021, China
Siyi He
1Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College/Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implement, Beijing 100021, China
Xinxin Yan
1Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College/Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implement, Beijing 100021, China
Fan Yang
1Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College/Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implement, Beijing 100021, China
Shaoli Zhang
1Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College/Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implement, Beijing 100021, China
Changfa Xia
1Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College/Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implement, Beijing 100021, China
Lin Lei
2Department of Cancer Prevention and Control, Shenzhen Center for Chronic Disease Control, Shenzhen 518020, China
Ji Peng
2Department of Cancer Prevention and Control, Shenzhen Center for Chronic Disease Control, Shenzhen 518020, China
Wanqing Chen
1Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College/Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implement, Beijing 100021, China
References
- 1.↵
- Zheng R,
- Zhang S,
- Zeng H,
- Wang S,
- Sun K,
- Chen R, et al.
- 2.↵
- 3.↵
- 4.↵National Bureau of Statistics of China. China Statistical Yearbook. [Cited 2022 April 5]. Available from: http://www.stats.gov.cn/tjsj/ndsj/.
- 5.↵
- Sun D,
- Li H,
- Cao M,
- He S,
- Lei L,
- Peng J, et al.
- 6.↵
- Tong-hai L.
- 7.↵
- Zeng H,
- Chen W,
- Zheng R,
- Zhang S,
- Ji JS,
- Zou X, et al.
- 8.↵
- Cao M,
- Ding C,
- Xia C,
- Li H,
- Sun D,
- He S, et al.
- 9.↵
- Liu Y,
- Chang CC,
- Marsh GM,
- Wu F.
- 10.↵
- Yang JY,
- Kim JB,
- Lee P,
- Kim SH.
- 11.↵
- 12.↵
- 13.↵
- Li M,
- Sun Y,
- Yang J,
- de Martel C,
- Charvat H,
- Clifford GM, et al.
- 14.↵
- Chelimo C,
- Wouldes TA,
- Cameron LD,
- Elwood JM.
- 15.↵
- Zhu B,
- Liu Y,
- Zuo T,
- Cui X,
- Li M,
- Zhang J, et al.
- 16.↵
- Chen W,
- Xia C,
- Zheng R,
- Zhou M,
- Lin C,
- Zeng H, et al.
- 17.↵
- 18.
- 19.↵
- Dogantemur S,
- Ozdemir S,
- Uguz A,
- Surmelioglu O,
- Dagkiran M,
- Tarkan O, et al.
- 20.↵
- de Martel C,
- Georges D,
- Bray F,
- Ferlay J,
- Clifford GM.
- 21.↵National Cancer Institute. Alcohol and Cancer Risk. [Cited 2022 April 10]. Available from: https://www.cancer.gov/about-cancer/causes-prevention/risk/alcohol/alcohol-fact-sheet.
- 22.↵World Health Organization. Global status report on alcohol and health (2018). [Cited 2022 April 10]. Available from: https://www.who.int/publications/i/item/9789241565639.
- 23.↵
- He F,
- Sha Y,
- Wang B.
- 24.↵
- 25.↵
- 26.↵
- 27.↵
- Hansen MS,
- Licaj I,
- Braaten T,
- Lund E,
- Gram IT.
- 28.↵
- 29.↵
- Pang Q,
- Qu K,
- Zhang J,
- Xu X,
- Liu S,
- Song S, et al.
- 30.↵
- Hecht SS,
- Hatsukami DK.
- 31.↵
- 32.↵
- Ansary-Moghaddam A,
- Huxley R,
- Barzi F,
- Lawes C,
- Ohkubo T,
- Fang X, et al.
- 33.
- McLaughlin JK,
- Lindblad P,
- Mellemgaard A,
- McCredie M,
- Mandel JS,
- Schlehofer B, et al.
- 34.↵
- 35.↵
- Besaratinia A,
- Pfeifer GP.
- 36.↵
- Ni X,
- Xu N,
- Wang Q.
- 37.
- Hackshaw AK,
- Law MR,
- Wald NJ.
- 38.
- Ding Y,
- Yu C,
- Han Z,
- Xu S,
- Li D,
- Meng X, et al.
- 39.↵
- Chang ET,
- Liu Z,
- Hildesheim A,
- Liu Q,
- Cai Y,
- Zhang Z, et al.
- 40.↵World Health Organization. Tobacco in China. [Cited 2022 April 5]. Available from: https://www.who.int/china/health-topics/tobacco.
- 41.↵
- Wang C.
- 42.↵
- Wang M,
- Luo X,
- Xu S,
- Liu W,
- Ding F,
- Zhang X, et al.
- 43.↵
- Chlebowski RT,
- Aragaki AK,
- Anderson GL,
- Pan K,
- Neuhouser ML,
- Manson JE, et al.
- 44.↵
- Aune D,
- Giovannucci E,
- Boffetta P,
- Fadnes LT,
- Keum N,
- Norat T, et al.
- 45.↵
- 46.↵
- Sofi F,
- Cesari F,
- Abbate R,
- Gensini GF,
- Casini A.
- 47.↵
- Tantamango-Bartley Y,
- Jaceldo-Siegl K,
- Fan J,
- Fraser G.
- 48.↵
- Liu X,
- Baecker A,
- Wu M,
- Zhou JY,
- Yang J,
- Han RQ, et al.
- 49.↵
- Ji X,
- Wang J,
- Li Z,
- Shen Q,
- Tuo J,
- Bi J, et al.
- 50.↵
- Chen JG,
- Zhang SW.
- 51.↵
- 52.↵
- Ge S,
- Feng X,
- Shen L,
- Wei Z,
- Zhu Q,
- Sun J.
- 53.↵
- 54.↵
- Szymañska K,
- Chen JG,
- Cui Y,
- Gong YY,
- Turner PC,
- Villar SP, et al.
- 55.↵
- Secretan B,
- Straif K,
- Baan R,
- Grosse Y,
- El Ghissassi F,
- Bouvard V, et al.
- 56.↵
- Barrett D,
- Ploner A,
- Chang ET,
- Liu Z,
- Zhang CX,
- Liu Q, et al.
- 57.↵
- Key TJ,
- Bradbury KE,
- Perez-Cornago A,
- Sinha R,
- Tsilidis KK,
- Tsugane S.
- 58.↵
- Murray JM,
- Coleman HG,
- Hunter RF.
- 59.↵
- Hardman AE.
- 60.↵
- 61.↵
- Pronk A,
- Ji BT,
- Shu XO,
- Chow WH,
- Xue S,
- Yang G, et al.
- 62.↵
- 63.↵
- Reulen RC,
- de Vogel S,
- Zhong W,
- Zhong Z,
- Xie LP,
- Hu Z, et al.
- 64.↵
- 65.↵
- Biller VS,
- Leitzmann MF,
- Sedlmeier AM,
- Berger FF,
- Ortmann O,
- Jochem C.
- 66.↵
- 67.↵
- 68.↵
- 69.↵
- De Pergola G,
- Silvestris F.
- 70.↵
- Liu Y,
- Warren Andersen S,
- Wen W,
- Gao YT,
- Lan Q,
- Rothman N, et al.
- 71.↵
- Chen Y,
- Liu L,
- Wang X,
- Wang J,
- Yan Z,
- Cheng J, et al.
- 72.↵
- Sohn W,
- Lee HW,
- Lee S,
- Lim JH,
- Lee MW,
- Park CH, et al.
- 73.↵
- Ren X,
- Zhang X,
- Zhang X,
- Gu W,
- Chen K,
- Le Y, et al.
- 74.↵
- Pan XF,
- Wang L,
- Pan A.
- 75.↵
- Wang Y,
- Zhao L,
- Gao L,
- Pan A,
- Xue H.
- 76.↵National Office for Cancer Prevention and Control. National Cancer Control and Prevention Plan (1986–2000). China Cancer. 1985; 9: 336–7.
- 77.↵
- Chen X-Z,
- Liu Y,
- Wang R,
- Zhang W-H,
- Hu J-K.
- 78.↵Chinese Center for Disease Control and Prevention. China National Plan for NCD Prevention and Treatment (2012-2015). [Cited 2022 April 5]. Available from: https://www.chinacdc.cn/en/ne/201207/t20120725_64430.html.
- 79.↵Bureau for Cancer Prevention and Control. China’s Cancer Prevention and Treatment Three-Year Action Plan (2015-2017). [Cited 2022 April 5]. Available from: http://www.nhc.gov.cn/jkj/s5878/201509/656437bc5c7e4cd0afb581de85be998a.shtml.
- 80.↵The Central Government of the People’s Republic of China. Healthy China 2030. [Cited 2022 April 5]. Available from: http://www.gov.cn/zhengce/2016-10/25/content_5124174.htm.
- 81.↵Bureau of Cancer Prevention and Control. Healthy China Action Plan (2019-2022). [Cited 2022 April 5]. Available from: http://www.nhc.gov.cn/jkj/s5878/201909/2cb5dfb5d4f84f8881897e232b376b60.shtml.
- 82.↵
- Qu C,
- Chen T,
- Fan C,
- Zhan Q,
- Wang Y,
- Lu J, et al.
- 83.↵
- Cao M,
- Fan J,
- Lu L,
- Fan C,
- Wang Y,
- Chen T, et al.
- 84.↵
- Liang X,
- Bi S,
- Yang W,
- Wang L,
- Cui G,
- Cui F, et al.
- 85.↵
- Liao X,
- Liang Z.
- 86.↵Bureau for Cancer Prevention and Control. Great Achievements for the Contol of Hepatitis B. [Cited 2022 April 5]. Available from: http://www.nhc.gov.cn/jkj/s3582/201307/518216575e544109b2caca07fca3b430.shtml.
- 87.↵
- Ribassin-Majed L,
- Lounes R,
- Clémençon S.
- 88.↵
- 89.↵ECNS.cn. China’s first domestic HPV vaccine earns WHO prequalification. [Cited 2022 April 15]. Available from: http://www.ecns.cn/news/2021-10-18/detail-ihasacat0472343.shtml.
- 90.↵
- Liu Y,
- Di N,
- Tao X.
- 91.↵
- Ji M,
- Huang Z,
- Ren J,
- Sun X,
- Wagner AL.
- 92.↵
- Yin Y.
- 93.↵China Anti-Cancer Association. National Cancer Week. [Cited 2022 June 10]. Available from: http://www.caca.org.cn/system/2020/03/27/020025350.shtml.
- 94.↵The Central Government of China. Healthy China Action (2019-2030). [Cited 2022 April 5]. Available from: http://www.gov.cn/xinwen/2019-07/15/content_5409694.htm.
- 95.↵
- Ding S-Z,
- Du Y-Q,
- Lu H,
- Wang W-H,
- Cheng H,
- Chen S-Y, et al.
- 96.↵
- 97.↵
- Cappuccio FP,
- Capewell S,
- Lincoln P,
- McPherson K.
- 98.↵
- Zhang N,
- Ma G.
- 99.↵People’s Republic of China. Report on Chinese Residents’ Chronic Diseases and Nutrition 2020. [Cited 2022 April 7]. Available from: http://www.gov.cn/xinwen/2020-12/24/content_5572983.htm.
- 100.↵National Cancer Center. Chinese Guideline for Cancer Registration: People’s Medical Publishing House; 2016.
- 101.↵
- Aberle DR,
- Adams AM,
- Berg CD,
- Black WC,
- Clapp JD,
- Fagerstrom RM, et al.
- 102.
- Duffy SW,
- Vulkan D,
- Cuckle H,
- Parmar D,
- Sheikh S,
- Smith RA, et al.
- 103.↵
- Ding R,
- Xiao Y,
- Mo M,
- Zheng Y,
- Jiang Y-Z,
- Shao Z-M.
- 104.↵
- Cao M,
- Li H,
- Sun D,
- He S,
- Yu Y,
- Li J, et al.
- 105.↵Bureau for Maternal and Child Helath. Report on China’s development of maternal and child health (2019). [Cited 2022 April 5]. Available from: http://www.nhc.gov.cn/fys/s7901/201905/bbd8e2134a7e47958c5c9ef032e1dfa2.shtml.
- 106.↵National Health Commission of the People’s Republic of China. Response to the Question suggested by the Second Session of the 13th National Committee of the Chinese People’s Political Consultative Conference. [Cited 2022 April 5]. Available from: http://www.nhc.gov.cn/wjw/tia/202009/6c18078d53e847b3afc50f412cd5df93.shtml.
- 107.↵Tianjin Municipal People’s Government. The interim data of the joint screening project for common malignant tumors. [Cited 2022 April 5]. Available from: http://www.tj.gov.cn/sy/tjxw/202108/t20210806_5526832.html.
- 108.↵The People’s Government of Zhejiang Province. Notice of the implementation plan of the “three exemptions and three benefits” health action for urban and rural residents in Zhejiang Province. [Cited 2022 April 5]. Available from: http://www.zj.gov.cn/art/2021/11/26/art_1229530772_2376859.html.
- 109.↵National Helath Commission of the People’s Republic of China. Response to the Question suggested by The Fourth Session of the 13th National Committee of the Chinese People’s Political Consultative Conference. [Cited 2022 April 8]. Available from: http://www.nhc.gov.cn/wjw/tia/202201/84ec994244ff4b1883c9556712c1a608.shtml.
- 110.↵National Health Commission of the People’s Republic of China. Response to Recommendation No. 8901 of the Fourth Session of the Thirteenth National People’s Congress 2021. [Cited 2022 April 8]. Available from: http://www.nhc.gov.cn/wjw/jiany/202112/0c05b5bc81cc4786975384fdb44cf7a4.shtml.
- 111.↵
- Sun Y,
- Zhu Z,
- Zhang J,
- Han P,
- Qi Y,
- Wang X, et al.
- 112.↵The Central Government of the People’s Republic of China. 74 drugs to be added to national insurance list. [Cited 2022 June 8]. Available from: http://english.www.gov.cn/statecouncil/ministries/202112/07/content_WS61aeb805c6d09c94e48a1cbd.html.
- 113.↵The Central Government of the People’s Republic of China. Reimbursement ratio for major disease increased to 60%. [Cited 2022 June 8]. Available from: http://www.gov.cn/xinwen/2019-05/12/content_5390775.htm.
- 114.↵National Clinical Research Center for Digestive Diseases, Chinese Society of Digestive Endoscopology, Chinese Society of Health Management, Chinese Digestive Endoscopist Committee of Chinese Endoscopist Association, Health Management and Physical Examination Committee of Digestive Endoscopy of Chinese Endoscopist Association, National Quality Control Center for Digestive Endoscopy, Society of Oncological Endoscopy of China, et al. China experts consensus on the protocol of early gastric cancer screening (2017, Shanghai). Chin J Dig Endosc. 2018; 35: 77–83.
- 115.↵General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer (2022 edition). J Clin Hepatol. 2022; 38: 288–303.
- 116.↵
- Luo H,
- Zhao Q,
- Wei W,
- Zheng L,
- Yi S,
- Li G, et al.
In this issue
Current cancer burden in China: epidemiology, etiology, and prevention
Maomao Cao, He Li, Dianqin Sun, Siyi He, Xinxin Yan, Fan Yang, Shaoli Zhang, Changfa Xia, Lin Lei, Ji Peng, Wanqing Chen
Cancer Biology & Medicine Aug 2022, 19 (8) 1121-1138; DOI: 10.20892/j.issn.2095-3941.2022.0231
Jump to section
- Article
- Abstract
- Introduction
- Cancer epidemiology
- Etiology and underlying modifiable risk factors
- Cancer prevention and control
- Expenditures and national insurance for cancer control
- Limitations and challenges in cancer prevention
- Grant support
- Conflict of interest statement
- Author contributions
- Acknowledgments
- References
- Figures & Data
- References
- Info & Metrics
Related Articles
- No related articles found.
Cited By...
- Cervical cancer prevention in China: where are we now, and whats next?
- Bronchoalveolar lavage fluid assessment facilitates precision medicine for lung cancer
- A retrospective analysis of mature T- and NK-cell lymphomas
- Blockade of CD300A enhances the ability of human NK cells to lyse hematologic malignancies
- Influence of sex on outcomes of liver transplantation for hepatocellular carcinoma: a multicenter cohort study in China
- Cancer-educated neutrophils promote lung cancer progression via PARP-1-ALOX5-mediated MMP-9 expression
- Prognostic significance of grade of malignancy based on histopathological differentiation and Ki-67 in pancreatic ductal adenocarcinoma
- DNA methylation biomarkers for early detection of gastric and colorectal cancers
- Treatment strategies for patients with HER2-positive gastric cancer
- Current therapeutic landscape and resistance mechanisms to larotrectinib
- Single-arm trials for domestic oncology drug approvals in China
- Cohort profile: design and methods of the Chinese colorectal, breast, lung, liver, and stomach cancer screening trial (C-BLAST)
- Targeting endoplasmic reticulum stress signaling in ovarian cancer therapy
- The inducible secreting TLR5 agonist, CBLB502, enhances the anti-tumor activity of CAR133-NK92 cells in colorectal cancer
- Regulatory role of exosomes in colorectal cancer progression and potential as biomarkers
- Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma
- The Hippo/YAP signaling pathway: the driver of cancer metastasis
- Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance
- Development of glioblastoma organoids and their applications in personalized therapy
- Neutrophils as key regulators of tumor immunity that restrict immune checkpoint blockade in liver cancer
- Smart drug delivery systems to overcome drug resistance in cancer immunotherapy
- Smart drug delivery systems to overcome drug resistance in cancer immunotherapy
- Early detection of gastric cancer in China: progress and opportunities